JMJulius Mueller

Julius Mueller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julius Mueller has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A New Endoscopic Device to Facilitate APC Treatment: First Multicenter Clinical Experience

    by Julius Mueller, Armin Kuellmer, Arthur Schmidt, Moritz Schiemer, Robert Thimme, Benjamin Walter

    Background and Study Aims Argon plasma coagulation (APC) is an established ablation technique, but limited by tangential probe orientation. ArgoCap was developed to allow precise, safe, and reproducible APC through visualizing the argon beam, shielding the probe, maintaining a defined distance, and enabling hybrid APC procedures. This study aimed to evaluate the clinical feasibility and safety of ArgoCap across multiple indications. Patients and Methods Between January 2022 and May 2025, 54 APC procedures using the ArgoCap were performed at three expert centers. Indications included Barrett’s mucosa, ectopic gastric mucosa, gastric angioectasia, gastric antral vascular ectasia, radiation proctitis, and other indications. Primary endpoint was technical success, defined as access to the lesions and macroscopically complete ablation. Secondary endpoints included technical complications, adverse events, and procedural time. Results The majority of lesions were located in the esophagus (70%), followed by stomach (19%) and rectum (11%). Median lesion size was 13 mm (range 2–240 mm). Median ablation and procedure times were 8 min (2–15 min) and 25 min (8–75 min), respectively. Technical success was achieved in 47 cases (87%); subtotal ablation (>90% of the lesion) was possible in 52 cases (96%). Technical difficulties occurred in 1 case (2%); primary complication (ulceration with subsequent bleeding) was observed in 1 case (2%). Conclusions The ArgoCap enables easy and precise APC in the upper and lower gastrointestinal tract across multiple indications. It facilitates lesion access and visualization, reduces unintended mucosal contact, and allows hybrid APC procedures.

  • Open Access

    Clip-Based Endoscopic Anastomotic Reduction in Patients with Dumping Syndrome and Postbariatric Hypoglycemia after Roux-en-Y Gastric Bypass

    by Armin Kuellmer, Matthias Kandler, Sandra Nagl, Katharina Laubner, Maximilian Meyer-Steenbuck, Julius Mueller, Rafael Kaeser, Lukas Sturm, Jochen Seufert, Robert Thimme, et al.

    Background and Aims Dumping syndrome (DS) and postbariatric hypoglycemia (PBH) represent common complications after Roux-en-Y gastric bypass (RYGB). Transoral outlet reduction (TORe) addresses the rapid passage of food through the gastrojejunal anastomosis which is central in pathophysiology. In this prospective multicenter study, technical feasibility and short-term clinical efficacy of a new clip-based endoscopic system (BARS) were evaluated. Methods Twenty-three consecutive patients at three centers in Germany were included. The primary endpoint was feasibility measured as reduction of anastomotic diameter and surface. Secondary endpoints included changes of the Dumping symptom score and glycaemia in modified oral glucose tolerance tests (mod. oGTT), anastomotic diameter, quality of life after 12 weeks and adverse events. Results The procedure was technically feasable in all cases. Median anastomotic diameter was reduced from 40 mm (IQR: 30–50) to 9 mm (IQR: 7–10); −77%) at baseline (p < 0.001). At week 12, median Sigstad-Score decreased from 17,5 (IQR: 12.8–21.0) to 5 (IQR: 0–11; p < 0.001). Median anastomotic diameter was still reduced to 20 mm (IQR: 12–30; p = 0.004; −47%). Modified oGTT demonstrated abolished DS in 3 of 23 patients (13%) while no effect was seen in PBH at 12 weeks. Median BMI decreased from 30.6 kg/m2 (IQR: 28–35.6) to 29.25 kg/m2 (IQR: 26.7–33.4; p = 0.001). Quality of life (QoL) improved significantly in five of eight subcategories of the SF-36. Conclusion Clip-based anastomotic reduction for DS and PBH seems feasible, safe and showed significant improvements in Sigstad scores and QoL in short-term analysis.

  • International, Multicenter Analysis of Endoscopic Full-Thickness Resection of Duodenal Neuroendocrine Tumors

    by Andreas Wannhoff, Zaheer Nabi, Leon M.G. Moons, Gregory Haber, Phillip S. Ge, Tobias Dertmann, Pierre H. Deprez, Wojciech Korcz, Christopher Bouvette, Julius Mueller, et al.

    INTRODUCTION: Nonexposed endoscopic full-thickness resection (EFTR) using a dedicated full-thickness resection device can be used to perform en bloc resection of subepithelial lesions throughout the gastrointestinal tract. In this article, we aim to evaluate the safety and efficacy of EFTR for the management of duodenal neuroendocrine tumors (dNETs). METHODS: This was an international multicenter retrospective study of device-assisted EFTR for dNET. Study outcomes included rates of technical success, R0 resection, and adverse events (AEs). RESULTS: A total of 171 patients were included across 35 centers. Lesions had a median size of 10 mm and were in the duodenal bulb in 143 cases (83.6%). Technical success was achieved in 164 (95.9%) and R0 resection in 123 cases (71.9%). The R0 resection rate for lesions located in the proximal third of the bulb was 62.0% compared with 83.9% for more distal locations ( P = 0.002). The R0 resection rate was not affected by lesion size or depth of invasion. On multivariable analysis, date of resection (2021 onward) and location distal to the proximal third of the duodenal bulb were independent predictors of R0 resection, but not case volume per participating center. Follow-up information was available for 114 patients (66.7%) and demonstrated 2 recurrences over a median follow-up of 10 months. Severe AEs occurred in 3 patients (1.8%). DISCUSSION: EFTR of dNET showed high technical success and R0 resection rates and very low rate of severe AEs. It could become endoscopic treatment of choice for dNET, at least for lesions not within proximity of the pylorus.


  • Open Access

    Outcome after colorectal full-thickness resection and management of recurrence

    by Julius Mueller, Valentin Miedtke, Armin Kuellmer, Moritz Schiemer, Dominik Bettinger, Robert Thimme, Arthur Schmidt

    Background and study aims Endoscopic full-thickness resection (eFTR) allows treatment of “difficult to resect” lesions not amenable to conventional endoscopic methods. Efficacy and safety of the system have already been proven in numerous studies. Follow-up data on outcome of colorectal eFTR and management of recurrences are still rare. Patients and methods All patients undergoing colorectal eFTR at our institution with at least one endoscopic follow-up examination were retrospectively analyzed. The primary endpoint was the rate of recurrent or residual lesions (RRLs) and the secondary endpoint was the rate of late adverse events (AEs). We further aimed to identify risk factors for RRLs and to describe their management. Results Between November 2014 and 2021, 141 patients underwent eFTR at University Medical Center Freiburg. Ninety-one patients fulfilled the inclusion criteria. Indications for eFTR were non-lifting adenoma (n = 65), subepithelial tumors (n = 18) and early carcinoma (n = 8). The median follow-up period was 17 months (range, 2–86). The overall RRL rate was 9.9% (9/91). A significant proportion of RRLs (6/9, 66%) were detected late. All RRLs occurred in the group of non-lifting adenoma, corresponding to a RRL rate of 13.8% in this subgroup. Thirty-three percent (3/9) were initially treated by hybrid eFTR. Of the RRLs, 66.6% could were successfully treated endoscopically. On χ2 analysis, the hybrid eFTR technique (P = 0.006) was associated with a higher rate of RRL. No late AEs occurred. Conclusions The rate of RRL after colorectal eFTR is low and the majority could be treated endoscopically. For non-lifting adenomas and early carcinomas, close follow-up is mandatory to detect late recurrence. Long-term outcomes after hybrid eFTR need further investigation.


  • Open Access

    ArgoCap – feasibility and safety of a novel over-the-scope device to facilitate endoscopic APC treatment

    by Julius Mueller, Gian Kayser, Armin Kuellmer, Moritz Schiemer, Dominik Bettinger, Florian Offensperger, Robert Thimme, Arthur Schmidt

    Argon plasma coagulation (APC) is an electrosurgical procedure used, among other indications, for treatment of dysplastic Barrett’s mucosa. Homogeneous and safe application can be compromised by va...


  • Accurate prediction of histological grading of intraductal papillary mucinous neoplasia using deep learning

    by Dominik Andreas Helmut Otto Schulz, Markus Heilmaier, Veit Phillip, Matthias Treiber, Ulrich Mayr, Tobias Lahmer, Julius Mueller, Ihsan Ekin Demir, Helmut Friess, Maximilian Reichert, et al.

    Background Risk stratification and recommendation for surgery for intraductal papillary mucinous neoplasm (IPMN) are currently based on consensus guidelines. Risk stratification from presurgery histology is only potentially decisive owing to the low sensitivity of fine-needle aspiration. In this study, we developed and validated a deep learning-based method to distinguish between IPMN with low grade dysplasia and IPMN with high grade dysplasia/invasive carcinoma using endoscopic ultrasound (EUS) images. Methods For model training, we acquired a total of 3355 EUS images from 43 patients who underwent pancreatectomy from March 2015 to August 2021. All patients had histologically proven IPMN. We used transfer learning to fine-tune a convolutional neural network and to classify “low grade IPMN” from “high grade IPMN/invasive carcinoma.” Our test set consisted of 1823 images from 27 patients, recruiting 11 patients retrospectively, 7 patients prospectively, and 9 patients externally. We compared our results with the prediction based on international consensus guidelines. Results Our approach could classify low grade from high grade/invasive carcinoma in the test set with an accuracy of 99.6 % (95 %CI 99.5 %–99.9 %). Our deep learning model achieved superior accuracy in prediction of the histological outcome compared with any individual guideline, which have accuracies between 51.8 % (95 %CI 31.9 %–71.3 %) and 70.4 % (95 %CI 49.8–86.2). Conclusion This pilot study demonstrated that deep learning in IPMN-EUS images can predict the histological outcome with high accuracy.


  • Open Access

    Current status of endoscopic full‐thickness resection with the full‐thickness resection device

    by Julius Mueller, Armin Kuellmer, Moritz Schiemer, Robert Thimme, Arthur Schmidt

    Endoscopic full‐thickness resection (EFTR) using the full‐thickness resection device (FTRD) is an integral part of diagnostic and therapeutic endoscopy. Since its market launch in Europe in 2014, its safety and effectiveness have been proven in numerous studies. Adaptations in design as well as new techniques, such as hybrid EFTR, expand the spectrum of the FTRD system. The following review is intended to provide an overview of the clinical application and current evidence of EFTR with the FTRD system.


  • ADVERSE EVENTS OF ENDOSCOPIC FULL-THICKNESS RESECTION: RESULTS FROM THE GERMAN AND DUTCH COLORECTAL EFTR REGISTRY

    by L.W. Zwager, J. Mueller, B. Stritzke, N.S. Montazeri, K. Caca, E. Dekker, P. Fockens, A. Schmidt, B.A. Bastiaansen

    Aims Endoscopic full-thickness resection (eFTR) is emerging as minimally invasive alternative to surgery for complex colorectal lesions. Previous eFTR reports demonstrated favorable safety, however large studies representing a generalizable estimation of adverse events (AEs) are lacking. Our aim was to provide further insight in AEs following colorectal eFTR. Methods This is an observational study of patients included in the German and Dutch colorectal eFTR registries between July 2015 and March 2021. All AEs were analysed. Results In total 1894 procedures were included. Total AE rate was 11.1% (n=211/1894; 95% confidence interval (CI)[9.7–12.6%]). Perforations occurred in 2.5% (n=47/1894; 95%CI[1.8–3.3%]), 27 direct and 20 delayed. Successful endoscopic closure was performed in 34.0% (13 direct and 1 delayed) and antibiotic treatment only in 4.3% (2 delayed). Appendicitis rate for appendiceal lesions was 10.0% (n=13/130; 95%CI[5.4–16.5%]) and 46.2% (6/13) could be treated conservatively. Severe AE rate requiring emergency surgery was 2.3% (n=43/1894; 95%CI[1.7–3.0%]). These concerned delayed perforations in 0.9% (n=17/1894) and direct perforations in 0.7% (n=14/1894). Delayed perforations occurred between day 1-10 post-eFTR (median of 2 days). In total, 58.8% (10/17) was located in the left-sided colon. Other severe AEs were appendicitis in 0.4% (n=7/1894), stenosis in 0.1% (n=2/1894), delayed bleeding in 0.1% (n=1/1894), severe pain following eFTR close to dentate line 0.1% (n=1/1894) and entrapment of grasper in clip 0.1% (n=1/1894). No procedure-related mortality occurred. Conclusions eFTR is a relative safe procedure with a low risk for severe AEs. Patients should be well informed on the risk of a delayed perforation and appendicitis. Publication Date: 14 April 2022 (online) © 2022. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Over-the-scope clip is an effective therapy for postbanding ulcer bleeding after initially successful transjugular intrahepatic portosystemic shunt therapy

    by Oscar Cahyadi, Karel Caca, Arthur Schmidt

    Postbanding ulcer bleeding (PBUB) is a potential deadly complication after esophageal variceal banding (EVB) in patients with portal hypertension, with a reported incidence of 2.6 % – 7.3 % [1]. Various treatment possibilities for PBUB, such as cyanoacrylate injection, self-expandable metal stents, and transjugular intrahepatic portosystemic shunt (TIPS), are commonly applied. Rebleeding from a postbanding ulcer after initially successful TIPS is rare, and no clear treatment algorithm is available. Here, we report on the successful application of an over-the-scope clip (OTSC) to treat a PBUB after successful TIPS not amenable to EVB or hemoclip. A 45-year-old man with a history of alcoholic liver cirrhosis (Child–Pugh stage B and model for end-stage liver disease score 6) underwent EVB and cyanoacrylate injection for bleeding esophageal varices at an external hospital. After recurrent drops in hemoglobin level, which was suspicious for intermittent refractory PBUB not visible on repeated esophagogastroduodenoscopy (EGD), he was referred to our unit for emergency TIPS. The TIPS procedure was uneventful. Thereafter, he had another drop in hemoglobin level. Urgent EGD revealed a spurting PBUB ([Fig. 1a]). Tissue scarring meant that repeat EVB or hemoclipping was not possible. Thus, an OTSC was applied (Type 12/6T; Ovesco Medical, Tübingen, Germany) ([Fig. 1 b]). Hemostasis was achieved immediately ([Fig. 1 c]). Second-look endoscopy revealed stable hemostasis, and the hemoglobin level remained stable during the subsequent clinical course ([Fig. 1 d], [Video 1]). Video 1 A patient with a postbanding ulcer bleeding after initially successful therapy with transjugular intrahepatic portosystemic shunt. Hemostasis was achieved with the application of an over-the-scope clip. No acute rebleeding was observed after extensive irrigation with saline. It should be noted that the use of OTSC in PBUB currently constitutes an off-label application. Hitherto, there is only one report known to us regarding the (off-label) use of OTSC in acute variceal bleeding [2]. Endoscopy_UCTN_Code_TTT_1AO_2AD